Scancell Holdings plc (AIM:SCLP)
9.85
+0.20 (2.07%)
Oct 31, 2025, 5:01 PM GMT+1
Scancell Holdings Employees
Scancell Holdings had 60 employees as of April 30, 2025. The number of employees decreased by 1 or -1.64% compared to the previous year.
Employees
60
Change (1Y)
-1
Growth (1Y)
-1.64%
Revenue / Employee
78.52K GBP
Profits / Employee
-204.53K GBP
Market Cap
102.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 60 | -1 | -1.64% |
| Apr 30, 2024 | 61 | 10 | 19.61% |
| Apr 30, 2023 | 51 | 11 | 27.50% |
| Apr 30, 2022 | 40 | 15 | 60.00% |
| Apr 30, 2021 | 25 | 3 | 13.64% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Spire Healthcare Group | 15,703 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
Scancell Holdings News
- 7 weeks ago - Scancell Holdings PLC (SCNLF) Full Year 2025 Earnings Call Highlights: Strategic Partnerships ... - GuruFocus
- 7 weeks ago - Full Year 2025 Scancell Holdings PLC Earnings Call Transcript - GuruFocus
- 7 weeks ago - Scancell Holdings Plc (SCNLF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Scancell Holdings plc 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 7 weeks ago - Scancell Holdings plc GAAP EPS of -1.26p, revenue of £4.7M - Seeking Alpha
- 7 weeks ago - Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025 - GlobeNewsWire
- 3 months ago - Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ - GlobeNewsWire
- 1 year ago - PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma - Business Wire